More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

Japanese Patent Office to grant key patent for Progenza

May 23, 2017 at 11:41 PM EDT · Issued by Cambium Bio Ltd

Filed with ASX · May 23, 2017 at 11:41 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/japanese-patent-office-to-grant-key-patent-for-progenza

Cambium Bio Ltd on 6ix

Story so far

  • Positive clinical trial results for ProgenzaMay 22, 2017
  • Regeneus and AGC collaborate on Progenza in JapanDec 29, 2016
  • Enrolment complete and positive safety in Progenza trialMay 16, 2016

Earlier from Cambium Bio

  • Positive clinical trial results for ProgenzaMay 22, 2017
  • Chinese patent granted on stem cell secretions technologyMar 27, 2017
  • Regeneus receives upfront payment of US$5.5m from AGCJan 22, 2017
  • Regeneus and AGC collaborate on Progenza in JapanDec 28, 2016
  • Japan UpdateOct 16, 2016

Later from Cambium Bio

  • RGS to receive milestone payment for successful Phase IJun 20, 2017
  • US patent allowed for Sygenus for acneJul 9, 2017
  • Appendix 4E RevisedAug 22, 2017
  • Regeneus receives R&D tax incentive refund of $2.6mAug 29, 2017
  • Sygenus shows longer lasting effect on pain than morphineSep 25, 2017
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer